Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VITCLEAR: PK of Ranibizumab and Aflibercept in AMD
NCT02174211Completed
- Sponsor
- King's College Hospital
- Start
- Jun 2014
- Primary completion
- Nov 2020
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Open-label trial of ranibizumab and aflibercept in age-related macular degeneration (AMD) (3 arms), sponsored by King's College Hospital. Primary endpoints: Ranibizumab half-life at 12 months and Aflibercept half-life at 12 months. Started Jun 2014; status: completed.
02
Drugs
ranibizumabaflibercept
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NCT02174211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02174211.